Skip to content

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.86B+2,204%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,265%
Immunome logo
ImmunomeIMNM
$1.9B+470%

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s enterprise value?
IDEAYA Biosciences, Inc. (IDYA) reported enterprise value of $2.8B in Q1 2026.
How has IDEAYA Biosciences, Inc.'s enterprise value changed year-over-year?
IDEAYA Biosciences, Inc.'s enterprise value increased by 110.3% year-over-year, from $1.33B to $2.8B.
What is the long-term trend for IDEAYA Biosciences, Inc.'s enterprise value?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s enterprise value has grown at a 44.1% compound annual growth rate (CAGR), from $473.65M to $2.95B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.